Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orynotide
- Development stage
- Unknown
- Lead developer
- Oryn Therapeutics
- Modality
- Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Orynotide (also known as ORTD-1 or ORYN-1001) is a novel engineered macrocyclic peptide therapeutic developed by Oryn Therapeutics. Bioinspired by theta-defensins (cyclic host-defense peptides), orynotide acts as an immunomodulator that targets complex protein surfaces and allosteric regulatory domains. Its primary mechanism of action involves the inhibition of tumor necrosis factor-alpha convertase (TACE/ADAM17) and the subsequent modulation of downstream inflammatory pathways, including the NF-kappaB pathway. Orynotide is designed to reprogram dysregulated immune networks rather than broadly suppressing them, and has been investigated in clinical trials for the treatment of rheumatoid arthritis and COVID-19-related pneumonia.
- Brand names
- Orynotides
- Other names
- rhesus theta-defensin-1RTD-1RTD1RTD 1
02
Targets
ADAM17 (A disintegrin and metalloprotease 17)
Beyond the preview
Go deeper on orynotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orynotide.